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Abstract
There is a critical need for safe and effective drugs for COVID-19.
Only remdesivir has received authorization for COVID-19 and has
been shown to improve outcomes but not decrease mortality.
However, the dose of remdesivir is limited by hepatic and kidney
toxicity. ACE2 is the critical cell surface receptor for SARS-CoV-2.
Here, we investigated additive effect of combination therapy using
remdesivir with recombinant soluble ACE2 (high/low dose) on Vero
E6 and kidney organoids, targeting two different modalities of
SARS-CoV-2 life cycle: cell entry via its receptor ACE2 and intracel-
lular viral RNA replication. This combination treatment markedly
improved their therapeutic windows against SARS-CoV-2 in both
models. By using single amino-acid resolution screening in haploid
ES cells, we report a singular critical pathway required for remde-
sivir toxicity, namely, Adenylate Kinase 2. The data provided here
demonstrate that combining two therapeutic modalities with dif-
ferent targets, common strategy in HIV treatment, exhibit strong
additive effects at sub-toxic concentrations. Our data lay the
groundwork for the study of combinatorial regimens in future
COVID-19 clinical trials.
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Introduction
In December of 2019, a novel coronavirus (SARS-CoV-2) crossed
species barriers to infect humans and was effectively transmitted
from person to person, leading to a pneumonia outbreak first
reported in Wuhan, China (Jiang et al, 2020; Zhou et al, 2020). This
virus causes coronavirus disease-19 (COVID-19) with influenza like
symptoms ranging from mild disease to severe lung failure and
multi-organ damage, eventually leading to death, especially in older
patients with other co-morbidities. SARS-CoV-2 shares multiple
similarities with the original SARS-CoV (Lu et al, 2020; Zhu et al,
2020). The receptor binding domain (RBD) of SARS-CoV-2 is similar
to the SARS-CoV RBD, suggesting a possible common host cell
receptor. The SARS-CoV receptor Angiotensin-converting enzyme 2
(ACE2) was indeed rapidly identified to also function as the critical
cell surface receptor for SARS-CoV-2 (Walls et al, 2020; Wan et al,
2020; Wrapp et al, 2020).
We were the first to shown that ACE2 counterbalances the effects
of Angiotensin (Ang) II in vivo and thereby protects the heart,
kidney, and, importantly, the lung via its enzymatic RAS activity
(Crackower et al, 2002; Imai et al, 2005). Moreover, we showed that
ACE2 is the critical SARS-CoV receptor in vivo using ACE2 mutant
mouse experiments and that SARS-CoV infections and even purified
Spike as well as a minimal Spike domain (RBD) can lead to ACE2
downregulation (Kuba et al, 2005), explaining why SARS-CoV, and
now SARS-CoV-2 infections cause severe lung failure: ACE2 is the
receptor for both viruses and downregulation of ACE2 via virus
binding results in loss of RAS tissue homeostasis which then drives
disease severity. Moreover, ACE2 expression and its regulation
in cardiovascular disease, gender being encoded on the X
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chromosome, or aging can explain and contributes to progression
and tissue distribution of COVID-19 as a multi-organ disease (Imai
et al, 2010). Recently, we reported that human recombinant
soluble ACE2 (hrsACE2; APN01) can significantly block early
SARS-CoV-2 infections by a factor of 1,000–5,000 (Monteil et al,
2020). HrsACE2 entered several clinical trials (Haschke et al, 2013;
Khan et al, 2017). Moreover, we recently described the first named
patient treatment with hrsACE2 of a patient with severe COVID-19
(Zoufaly et al, 2020). HrsACE2 has entered a placebo controlled,
double-blind, phase 2b trial in severe COVID-19 patients (www.c
linicaltrials.gov, NCT04335136), acting as a molecular decoy to
block virus entry, and as a regulator of the renin–angiotensin
system.
As the only drug, remdesivir has received FDA approval for
the treatment of COVID-19 (U.S. Food and Drug Administration,
2020). Remdesivir is a RNA polymerase inhibitor, which acts as
an adenosine analog, incorporating into nascent viral RNA chains,
thus leading to their premature termination (Gordon et al, 2020a;
Gordon et al, 2020b). Initially developed to block replication of
Ebola and Marburg viruses, remdesivir shows also anti-viral activ-
ity against coronaviruses including MERS, SARS-CoV, and SARS-
CoV-2 (Malin et al, 2020; Simonis et al, 2020). However, its effi-
cacy on viral load and mortality in severe COVID-19 patients is
still unclear (Wang et al, 2020b). Moreover, it has been reported
that remdesivir can exert hepatic and kidney toxicity (Grein et al,
2020; Wang et al, 2020b). In this study, we report a single amino
resolution screen on remdesivir toxicity uncovering a specific
mechanism of remdesivir intracellular activation required for cyto-
toxity. Importantly, combining two different modalities of virus
control, blocking entry via hrsACE2 and blocking intracellular
viral RNA replication via remdesivir, results in additive effects in
SARS-CoV-2-infected cells and human stem cell-derived kidney
organoids, reducing the doses of both hrsACE2 and remdesivir to
much lower and safer levels.
Results and Discussion
We hypothesized that combining two different modalities of anti-viral
activity using remdesivir (Gordon et al, 2020b) and targeting SARS-
CoV-2 entry into cells by hrsACE2 (Monteil et al, 2020) might show
additive effects. We first used Vero E6 cells as a commonly used and
robust model of SARS-CoV-2 infection (Monteil et al, 2020). In Vero E6
cells, infected with SARS-CoV-2 at a MOI of 20, both remdesivir and
hrsACE2 as single agents significantly reduced virus load in a dose-
dependent manner (Fig 1A and B), confirming previous data (Monteil
et al, 2020; Wang et al, 2020a). Based on the above dose responses, we
determined the IC50 and IC90 values for both remdesivir and hrsACE2
(Table 1). Of note, previous studies have reported different IC50/IC90
values for remdesivir, which is probably due to the different cell types
used, different MOI of infections, different SARS-CoV-2 sub-strains,
and/or measurements at different time points post-infection (Fredian-
syah et al, 2020; Jeon et al, 2020; Pizzorno et al, 2020; Wang et al,
2020a). Taken together, performing careful side-by-side comparisons in
Vero E6 cells, hrsACE2 and remdesivir exhibit comparable efficacy to
reduce SARS-CoV-2 infections.
In remdesivir-treated patients, an elevation of enzymes ALT
and AST and creatinine have been reported (Mulangu et al, 2019;
Grein et al, 2020), indicative of liver and kidney toxicity. To
investigate this phenomenon, we have investigated the toxicity
of remdisivir in more relevant and advanced in vitro model. Our
complex kidney organoids can be readily infected with SARS-
CoV-2 (Monteil et al, 2020) and are an established model to
study various aspects of kidney physiology and pathology (Gar-
reta et al, 2019). Liver spheroids of primary human hepatocytes
recapitulate the molecular profiles of human liver at the
proteomic, transcriptomic, and metabolomics level for multiple
weeks in culture (Bell et al, 2016; Bell et al, 2017; Vorrink et al,
2017). Consequently, they outperform other hepatic cell models
(Bell et al, 2017) and culture paradigms (Bell et al, 2018) in
multi-center trials and a large toxicity screen using 123 hepato-
toxic and non-toxic control drugs found this spheroid system to
be the most predictive model for drug-induced liver injury (Vor-
rink et al, 2018). To evaluate cytotoxicity of remdesivir and
hrsACE2, we exposed Vero E6 cells, kidney organoids, and liver
spheroids to different concentrations of remdesivir alone or in
combination with hrsACE2 and assessed cell viability. Remde-
sivir exhibited significant toxicity in kidney organoids and liver
spheroids at doses similar or lower than the effective dose to
block SARS-CoV-2 replication (Table 2), in line with clinical
findings of liver and kidney injury in patients (Grein et al, 2020;
Wang et al, 2020b). By contrast, CC50 values for hrsACE2 in
Vero E6 cells, kidney organoids, and liver spheroids were mark-
edly lower that the effective dose to inhibit the SARS-CoV-2 viral
load (Tables 1 and 2). These data show that remdesivir, but not
hrsACE2, exhibits liver and kidney toxicity, as determine by
engineered human tissues, at doses that are required to effec-
tively control the SARS-CoV-2 infection.
To identify the critical intracellular pathways and interactions
that are required for remdesivir cytotoxicity, we performed an unbi-
ased chemical mutagenesis screen in mouse haploid stem cells
under strong remdesivir selection (50 µM, Fig 2A). This approach
allows to uncover the entire spectrum of mutations resulting in
resistance to remdesivir cytotoxicity: loss-of-function, gain-of-
function, or neomorph alleles (Horn et al, 2018). After ENU
A B
Figure 1. Blocking entry and replication of SARS-CoV-2 infections.
A, B (A) Remdesivir and (B) hrsACE2 inhibition of SARS-CoV-2 infections of
Vero E6 cells. Both drugs, and murine recombinant soluble ACE2
(mrsACE2, control treatment), were used at the indicated concentrations.
Viral RNA level was determined by qRT–PCR 15 h after inoculation of
SARS-CoV-2 (Swedish isolate, 106 PFU).
Data information: Error bars show mean  SD from biological triplicate. n = 3,
*P < 0.05; **P < 0.01; one-way ANOVA followed by Student’s t-test between
internal groups. P-values are listed in Appendix Table S1.
Source data are available online for this figure.
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mutagenesis and remdesivir selection of more than 15 million cells,
numerous colonies emerged, whereof the resistance of the five most
viable clones was validated (Fig 2B). Whole exome sequencing
revealed that all five clones resistant to remdesivir harbor a point
mutation in the same unique gene, namely, the Ak2 gene (Fig 2C).
Ak2 encodes Adenylate kinase 2, an enzyme localized in the mito-
chondrial intermembrane space that maintains adenine nucleotide
homeostasis by catalyzing the reversible reaction AMP + ATP =
2ADP (Noma, 2005). While only one essential isoform is present in
bacteria and lower eukaryotes, the genomes of higher vertebrates
encode multiple isoforms, suggesting functional redundancy (Liu
et al, 2019). AK2 is extremely well conserved from mice to
humans including conversation of all residues that are mutated in
the resistant clones (Fig 2D). One of the four independent AK2
mutations identified resides in a splice acceptor region indicating
a loss of function on the protein level. Using molecular modeling,
the other three mutations directly or indirectly affect nucleotide
binding sites (Fig 2E), pointing to a loss or reduction of AK2 cata-
lytic activity. Given that nucleoside analogs like remdesivir
require intracellular enzymatic activation (Eastman et al, 2020),
our data indicate that remdesivir gets specifically activated by
AK2 in the mitochondrial intermembrane space (Fig 2F). Thus,
not excluding additional molecules and pathways, our screen has
identified a critical enzyme that is required for remdesivir cyto-
toxicity.
Based on remdesivir toxicity in organoids, we speculated that
combining hrsACE2 and remdesivir could enhance their respective
anti-viral efficacies and thereby, importantly, reduce the concen-
trations required for therapeutic effects to doses below the toxic
range in our organotypic assays. In healthy volunteers, Cmax of
remdesivir was found to be around 7.3 µM after a 225 mg dose
(Humeniuk et al, 2020), which is in line with loading doses and
pharmacokinetics (PK) in critically ill COVID-19 patients (Tem-
pestilli et al, 2020). Taking into account these data and our
measured IC50 value of remdesivir (Table 1), we used a dose of
remdesivir of 4 µM for combination assays. Combinatorial treat-
ment of Vero E6 cells with hrsACE2 (200 µg/ml) and low dose
remdesivir (4 µM) indeed reduced the viral load by 60%
compared to hrsACE2 alone (Fig 3A). Importantly, we observed
similar findings in SARS-CoV-2 infected kidney organoids
(Fig 3B). However, at the dose used, hrsACE2 (200 µg/ml) alone
already strongly inhibited viral load and additive effects were not
statistically significant. Strikingly, however, low doses of hrsACE2
doses (5 and 10 µg/ml) showed additive effects in combination
with low dose remdesivir, resulting in strong and highly signifi-
cant reduction of SARS-CoV-2 infectivity in Vero E6 cells (Fig 3C)
and kidney organoids (Fig 3D). Haschke et al have previously
reported the pharmacokinetic of hrsACE2, the same molecule we
use for our current study, in healthy volunteers in a phase 1 clini-
cal trial (Haschke et al, 2013). The human pharmacokinetic data
indicate that a concentration of 5–10 µg/ml of hrsACE2 is reached
in plasma between 2 and 8 h post-administration by administrat-
ing 800 µg/kg. Although one has to await the pharmacokinetic
data for hrsACE2 in the phase 2b clinical trial in severe COVID-19
patients, combining hrsACE2 with a viral RNA polymerase inhi-
bitor such as remdesivir should allow to reduce the dose of both
drugs and for hrsACE2 to reach an effective in vivo anti-viral
concentrations, at the doses currently administered to the
patients.
Finally, we tested whether this combination treatment would
reduce the yield of infectious progeny virus. Intriguingly, treatment
with low dose hrsACE2 significantly reduced the yield of progeny
virus at 15 hpi to a much larger extent than it inhibited viral RNA
(Fig 3E). This effect in the reduction of viral progeny was even more
pronounced 48 hpi (Fig 3F). By contrast, low dose remdesivir had
only minor effects on the generation of infectious progeny virus at
early as well as later time points (Fig 3E and F). Importantly,
combining both drugs at low dose resulted in a significantly reduced
yield of viral progeny (Fig 3E and F). These data indicate that
combination therapies targeting two different critical paths of SARS-
CoV-2 infection, namely, viral entry and replication, can enhance
the therapeutic effects on viral load and, most importantly, viral
progeny.
Previously, we provided the first genetic evidence that ACE2
functions as a negative regulator of the renin–angiotensin system
(RAS) in multiple tissues such as the cardiovascular system
(Crackower et al, 2002). We also showed in genetic experiments
that ACE2 is the critical receptor for SARS-CoV in vivo and that
ACE2 protects the lung from injury, providing a molecular expla-
nation for the severe lung failure and death due to SARS-CoV
infections (Imai et al, 2005; Kuba et al, 2005). The data provided
here significantly extend these findings demonstrating that
combining two therapeutic modalities with different targets,
exhibit strong additive effects at sub-toxic concentrations. The
possibility of combining neutralizing antibodies targeting SARS-
CoV-2 spike protein with remdesivir has also to be considered and
investigated as a therapeutic strategy. These findings are reminis-
cent of the breakthrough in HIV therapeutics that was bought
about by simultaneous targeting of multiple distinct pathways in
the viral replication cycle (Gulick et al, 1997; Hammer et al,
1997). 2D-cellular models (like Vero/Vero E6 cells) are an impor-
tant piece of data to initiate clinical studies and are a system
commonly used for drug screening but most of the drugs tested
fail in clinical trial, highlighting the limitation of the system. Using
human organoid model for drugs testing might lead to a better
selection of drugs that could pass the clinical trial. Even if it does
not assure a success in clinical trial, our data lay the groundwork
for the study of combinatorial regimens in future COVID-19 clini-
cal trials.
Table 2. CC50 data for remdesivir and hrsACE2 in Vero E6 cells, liver
spheroids, and kidney organoids
Compound Vero Liver Kidney
hrsACE2 6,259 µg/ml 633 µg/ml >800 µg/ml
Remdesivir 98.26 µM 6.77 µM 10.5 µM










20 15 h 4.02 5.85
hrsACE2 Vero
E6
20 15 h 6.08 18.29
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Figure 2. Forward mutagenesis approach identifies remdesivir genetic interactions.
A Schematic of the chemical mutagenesis approach.
B Cell viability of isolated cell clones and WT AN3–12 cells following 72 h remdesivir treatment with the indicated doses. Mean  SEM of 2–4 biological replicates is
displayed.
C Ak2 mutations identified in the resistant clones analyzed in (B).
D Protein sequence alignment of mouse and human AK2. Black stars indicate residues involved in nucleotide binding. Black boxes mark sites mutated in the identified
cell clones with alternative residues indicated above.
E Structure of human AK2 in complex with bis(adenosine)-5’-tetraphosphate (pdb:2c9y). Ak2 mutations identified in the remdesivir resistance screen are highlighted in
magenta.
F Schematic of remdesivir cellular uptake and intracellular activation. Modified from Eastman et al (2020).
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Material and Methods
Virus
SARS-CoV-2 was isolated on Vero-E6 cells, from a nasopharyngeal
sample of a patient in Sweden (Monteil et al, 2020). Virus titers
were determined using a plaque assay as previously described
(Becker et al, 2008) with fixation of cells 72 h post-infection. The
SARS-CoV-2 isolate was sequenced by Next-Generation Sequencing
(Genbank accession number MT093571).
Preparation of soluble recombinant human
Clinical-grade human recombinant soluble ACE2 (hrsACE2, APN01,
amino acids 1–740) was produced by Polymun Scientific (contract
manufacturer) from CHO cells according to Good Manufacturing
A B C
D E F
Figure 3. Combined effect of remdesivir and hrsACE2 in blocking entry and replication of SARS-CoV-2 infections.
A Treatment of SARS-CoV-2 (106 PFU) infected Vero-E6 cells with human recombinant soluble ACE 2 (hrsACE2) (200 µg/ml) and remdesivir (Remd. 4 µM). Viral RNA
level was determined at 15 h after virus inoculation.
B Treatment of SARS-CoV-2 (106 PFU) infected human kidney organoids with hrsACE2 (200 µg/ml) and/or remdesivir (Remd. 4 µM). Viral RNA was determined by
qRT–PCR 72 h after the inoculation of 106 PFU of SARS-CoV-2.
C Treatment of SARS-CoV-2 (106 PFU) infected Vero-E6 cells with clinical doses of hrsACE2 (5 and 10 µg/ml) and remdesivir (Remd. 4 µM).
D Treatment of SARS-CoV-2 (106 PFU) infected kidney organoids with hrsACE2 (10 µg/ml) and remdesivir (4 µM).
E, F Progeny virus released from untreated Vero-E6 cells or Vero-E6 cells treated with clinical doses of hrsACE2 (5 and 10 µg/ml) and remdesivir (Remd. 4 µM). Progeny
was determined (E) 15 h and (F) 48 h post-infection (hpi).
Data information: Error bars show mean  SD from biological triplicate. n = 3, *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; one-way ANOVA followed by
Students t-test between internal groups. P-values are listed in Appendix Table S1.
Source data are available online for this figure.
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Practice guidelines and formulated as a physiologic aqueous solu-
tion (Haschke et al, 2013; Monteil et al, 2020).
Liver and kidney cytotoxicity assays
To determine whether hrsACE2 or remdesivir at effective anti-viral
doses are toxic to liver and kidney cells, we treated primary human
liver spheroids (Bell et al, 2016; Stebbing et al, 2020) and human
stem cell-derived kidney organoids (Garreta et al, 2019) with several
concentration of hrsACE2 (50–800 µg/ml) or remdesivir (4–80 µM)
in triplicate for 24 h. Three days post-treatment (for kidney orga-
noids) and 15 h post-treatment (for liver spheroids) cytotoxicity
(CC50) was determined using the CellTiter-Glo Luminescent cell
viability assay (Promega) following manufacturer’s protocol using
50 µl of CellTiter-Glo Reagent per well. Cytotoxicity of remdesivir
in AN3–12 mouse embryonic stem cells was also assessed using the
CellTiter-Glo viability assay after 72 h incubation with the indi-
cated remdesivir doses.
Treatments of Vero E6 cells with hrsACE2 and remdesivir
Vero E6 cells were seeded in 48-well plates (5.104 cells per well)
(Sarstedt) in DMEM containing 10% FBS. Twenty four hours
post-seeding, dilution of remdesivir was prepared in DMEM 5%
FBS in a final volume of 100 µl per well. Cells were treated with
remdesivir or mock-treated for one hour. During this incubation
time, hrsACE2 was mixed with the virus (1:1) in a final volume
of 100 µl per well in DMEM (5% FBS) at 37°C for 30 min; then,
remdesivir was added (or not) to the mixes before infection.
Vero E6 were infected either with mixes containing hrsACE2/
SARS-CoV-2, remdesivir/SARS-CoV-2, or hrsACE2/remdesivir/
SARS-CoV-2 for 1 h. After 1 h, cells were washed three times
with PBS and 200 µl of DMEM 5%FBS containing remdesivir
4 µM, hrsACE2 5 µg/ml or 10 µg/ml or combinations were added
to the cells for 15 and 48 h. Fifteen hours post-infection, super-
natants were removed and saved for titration, and cells were
washed three times with PBS and then lysed using TrizolTM
(Thermofisher) before analysis by qRT–PCR for viral RNA detec-
tion. Forty eight hours post-infection, supernatants were removed
and saved for titration. Infectious progeny virus in supernatants
was titered using a plaque assay with fixation of cells 72 h post-
infection.
Treatments of kidney organoids with hrsACE2 and remdesivir
The kidney organoid model for SARS-CoV-2 infection has been
described recently (Monteil et al, 2020). Dilution of remdesivir
was prepared in DMEM 5% FBS in a final volume of 100 µl per
well. Kidneys were treated with remdesivir or mock-treated for
one hour. During this incubation time, hrsACE2 (10 or 200 µg/
ml) was mixed with 10^6 PFU of virus (1:1) in a final volume
of 100 µl per well in Advanced RPMI medium (Thermo Fisher)
at 37°C for 30 min; then, remdesivir was added or not to mixes
before infection. Kidney supernatants were then removed, and
kidneys were infected either with mixes containing hrsACE2/
SARS-CoV-2, remdesivir/SARS-CoV-2, or hrsACE2/remdesivir/
SARS-CoV-2 for 3 days. Three days post-infection, supernatants
were removed, and kidneys were washed three times with PBS
and then lysed using TrizolTM (Thermofisher) before analysis by
qRT–PCR for viral RNA detection.
Mutagenesis screen, exome sequencing, and analysis
The screening procedure and the data analysis were extensively
described previously (Horn et al, 2018). In brief, AN3–12 mouse
embryonic haploid stem cells were cultured in DMEM high glucose
(Sigma-Aldrich) supplemented with glutamine, fetal bovine serum
(15%), streptomycin, penicillin, non-essential amino acids, sodium
pyruvate, b-mercaptoethanol, and LIF. Cells were mutagenized
with 0.1 mg/ml Ethylnitrosourea for two hours at room tempera-
ture 24 h prior to selection with 50 µM remdesivir. Two weeks
later, resistant clones were isolated and subjected to remdesivir
cytotoxicity assays and gDNA extraction using the Gentra Puregene
Tissue Kit (Qiagen). Paired end, 150 bp whole exome sequencing
was performed on an Illumina Novaseq 6000 instrument after
precapture-barcoding and exome capture with the Agilent SureS-
elect Mouse All Exon kit. For data analysis, raw reads were aligned
to the reference genome mm9. Variants were identified and anno-
tated using GATK (v.3.4.46) and snpEff (v.4.2). Remdesivir resis-
tance causing alterations were identified by allelism only
considering variants with moderate or high effect on protein and a
read coverage > 20.
qRT–PCR
Samples were extracted using Direct-zol RNA MiniPrep kit
(Zymo Research). qRT–PCR was performed using E-gene SARS-







RNase P was used as an endogenous gene control to normalize the





Statistical analyses were conducted using GraphPad Prism 8
(GraphPad), and significance was determined by one-way ANOVA
followed by Student’s t-test for internal groups. Error bars show
mean  SD from biological triplicate.
Data availability
All source data of this study are available online. Other data that
support the findings of this study are available from the correspond-
ing authors upon request.
Expanded View for this article is available online.
6 of 8 EMBO Molecular Medicine e13426 | 2020 ª 2020 The Authors
EMBO Molecular Medicine Vanessa Monteil et al
Acknowledgements
We thank all members of our laboratories for critical input and suggestions.
This project has received funding from the Innovative Medicines Initiative 2
Joint Undertaking (JU) under grant agreement no. 101005026. The JU receives
support from the European Union’s Horizon 2020 research and innovation
program and EFPIA. J.M.P. is supported by the Canada 150 Research Chair
program, the von Zastrow foundation and COVID-19 grants from CIHR and
the Austrian WWTF. This work was partially supported by the CIHR grants
440347, FDN143285, and OV3-170344. This work has received funding from
the European Research Council (ERC) under the European Union’s Horizon
2020 research and innovation program (StG-2014-640525_REGMAMKID to
N.M.). A.M supported by Swedish research council (2018-05766). NM is also
supported by the Instituto de Salud Carlos III (ACE2ORG), the Spanish
Ministry of Economy and Competitiveness/FEDER (SAF2017-89782-R), the
Generalitat de Catalunya and CERCA Programme (2017 SGR 1306), and
Asociacion Espa~nola contra el Cancer (LABAE16006). C.H.P. is supported by
Marie Skłodowska-Curie Individual Fellowships (IF) grant agreement no.
796590. N.M and C.H.P are supported by the EFSD/Boehringer Ingelheim
European Research Programme in Microvascular Complications of Diabetes.
Author contributions
VM performed all of the experiments involving SARS-CoV-2, including isolation,
and helped with manuscript writing/editing. MD performed mutagenesis
screening/sequence analysis. VML and SY conducted work with the liver
spheroid system. VML helped with manuscript editing. HK performed all the
qRT–PCR for virus involved experiment. GW, HZ, and ASS developed and
produced clinical-grade hrsACE2. CHP developed derived kidney organoids.
JMP, NM, MH, and AM designed the project and wrote the manuscript.
Conflict of interest
JMP declares a conflict of interest as a founder and shareholder of Apeiron Biologics.
GW is an employee of Apeiron Biologics. AS is a consultant to Apeiron Biologics. VML
is co-founder, CEO, and shareholder of HepaPredict AB and discloses consultancy
work for Enginzyme AB. MH is co-founder, CEO, and shareholder of Acus Laborato-
ries GmbH and CSO of JLP Health GmbH. MD is employee of Acus Laboratories
GmbH and JLP Health GmbH. All other authors declare no competing interests.
References
U.S. Food and Drug Administration (2020) in: Administration U.F.a.D. (Ed.).
https://www.fda.gov/media/13764/download
Becker MM, Graham RL, Donaldson EF, Rockx B, Sims AC, Sheahan T, Pickles
RJ, Corti D, Johnston RE, Baric RS et al (2008) Synthetic recombinant bat
SARS-like coronavirus is infectious in cultured cells and in mice. Proc Natl
Acad Sci USA 105: 19944 – 19949
Bell CC, Dankers ACA, Lauschke VM, Sison-Young R, Jenkins R, Rowe C,
Goldring CE, Park K, Regan SL, Walker T et al (2018) Comparison of
hepatic 2D sandwich cultures and 3D spheroids for long-term toxicity
applications: a multicenter study. Toxicol Sci 162: 655 – 666
Bell CC, Hendriks DF, Moro SM, Ellis E, Walsh J, Renblom A, Fredriksson
Puigvert L, Dankers AC, Jacobs F, Snoeys J et al (2016) Characterization of
primary human hepatocyte spheroids as a model system for drug-induced
liver injury, liver function and disease. Sci Rep 6: 25187
Bell CC, Lauschke VM, Vorrink SU, Palmgren H, Duffin R, Andersson TB,
Ingelman-Sundberg M (2017) Transcriptional, functional, and mechanistic
comparisons of stem cell-derived hepatocytes, HepaRG cells, and three-
dimensional human hepatocyte spheroids as predictive in vitro systems
for drug-induced liver injury. Drug Metab Dispos 45: 419 – 429
Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira-
dos-Santos AJ, da Costa J, Zhang L, Pei Y et al (2002) Angiotensin-converting
enzyme 2 is an essential regulator of heart function. Nature 417: 822 – 828
Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, Hall
MD (2020) Correction to Remdesivir: a review of its discovery and
development leading to human clinical trials for treatment of COVID-19.
ACS Cent Sci 6: 1009
Frediansyah A, Nainu F, Dhama K, Mudatsir M, Harapan H (2020) Remdesivir
and its antiviral activity against COVID-19: A systematic review. Clin
Epidemiol Glob Health. https://doi.org/10.1016/j.cegh.2020.07.011
Garreta E, Prado P, Tarantino C, Oria R, Fanlo L, Marti E, Zalvidea D, Trepat X,
Roca-Cusachs P, Gavalda-Navarro A et al (2019) Fine tuning the
extracellular environment accelerates the derivation of kidney organoids
from human pluripotent stem cells. Nat Mater 18: 397 – 405
Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Gotte M (2020a) The antiviral
compound remdesivir potently inhibits RNA-dependent RNA polymerase
from Middle East respiratory syndrome coronavirus. J Biol Chem 295:
4773 – 4779
Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, Gotte M
(2020b) Remdesivir is a direct-acting antiviral that inhibits RNA-
dependent RNA polymerase from severe acute respiratory syndrome
coronavirus 2 with high potency. J Biol Chem 295: 6785 – 6797
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G,
Green ML, Lescure FX et al (2020) Compassionate use of Remdesivir for
patients with severe Covid-19. N Engl J Med 382: 2327 – 2336
Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman
DD, Valentine FT, Jonas L, Meibohm A et al (1997) Treatment with
indinavir, zidovudine, and lamivudine in adults with human
immunodeficiency virus infection and prior antiretroviral therapy. N Engl J
Med 337: 734 – 739
Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS,
Eron JJ, Feinberg JE, Balfour HH, Deyton LR et al (1997) A controlled trial
of two nucleoside analogues plus indinavir in persons with human
immunodeficiency virus infection and CD4 cell counts of 200 per cubic
millimeter or less. N Engl J Med 337: 725 – 733
Haschke M, Schuster M, Poglitsch M, Loibner H, Salzberg M, Bruggisser M,
Penninger J, Krahenbuhl S (2013) Pharmacokinetics and
pharmacodynamics of recombinant human angiotensin-converting
enzyme 2 in healthy human subjects. Clin Pharmacokinet 52: 783 – 792
Horn M, Kroef V, Allmeroth K, Schuller N, Miethe S, Peifer M, Penninger JM,
Elling U, Denzel MS (2018) Unbiased compound-protein interface
The paper explained
Problem
To date, there are no effective drugs for COVID-19. Only remdesivir
has received authorization for COVID-19 and has been shown to
improve outcomes but not decrease mortality.
Results
We have demonstrated an additive effect of combination therapy using
remdesivir with recombinant soluble ACE2. This combination treatment
markedly improved their therapeutic windows against SARS-CoV-2.
Impact
Our data lay the groundwork for the study of combinatorial regimens
in future COVID-19 clinical trials and lead to better therapy in future.
ª 2020 The Authors EMBO Molecular Medicine e13426 | 2020 7 of 8
Vanessa Monteil et al EMBO Molecular Medicine
mapping and prediction of chemoresistance loci through forward genetics
in haploid stem cells. Oncotarget 9: 9838 – 9851
Humeniuk R, Mathias A, Cao H, Osinusi A, Shen G, Chng E, Ling J, Vu A,
German P (2020) Safety, tolerability, and pharmacokinetics of Remdesivir,
an antiviral for treatment of COVID-19, in healthy subjects. Clin Transl Sci
13: 896 – 906
Imai Y, Kuba K, Ohto-Nakanishi T, Penninger JM (2010) Angiotensin-
converting enzyme 2 (ACE2) in disease pathogenesis. Circ J 74: 405 – 410
Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T,
Leong-Poi H et al (2005) Angiotensin-converting enzyme 2 protects from
severe acute lung failure. Nature 436: 112 – 116
Jeon S, Ko M, Lee J, Choi I, Byun SY, Park S, Shum D, Kim S (2020)
Identification of antiviral drug candidates against SARS-CoV-2 from FDA-
approved drugs. Antimicrob Agents Chemother 64: e00819 – 20
Jiang S, Du L, Shi Z (2020) An emerging coronavirus causing pneumonia
outbreak in Wuhan, China: calling for developing therapeutic and
prophylactic strategies. Emerg Microbes Infect 9: 275 – 277
Khan A, Benthin C, Zeno B, Albertson TE, Boyd J, Christie JD, Hall R, Poirier G,
Ronco JJ, Tidswell M et al (2017) A pilot clinical trial of recombinant
human angiotensin-converting enzyme 2 in acute respiratory distress
syndrome. Crit Care 21: 234
Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng
W et al (2005) A crucial role of angiotensin converting enzyme 2 (ACE2) in
SARS coronavirus-induced lung injury. Nat Med 11: 875 – 879
Liu H, Pu Y, Amina Q, Wang Q, Zhang M, Song J, Guo J, Mardan M (2019)
Prognostic and therapeutic potential of Adenylate kinase 2 in lung
adenocarcinoma. Sci Rep 9: 17757
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N
et al (2020) Genomic characterisation and epidemiology of 2019 novel
coronavirus: implications for virus origins and receptor binding. Lancet
395: 565 – 574
Malin JJ, Suarez I, Priesner V, F€atkenheuer G, Rybniker J (2020) Remdesivir
against COVID-19 and other viral diseases. Clin Microbiol Rev 34: e00162-
00120
Monteil V, Kwon H, Prado P, Hagelkruys A, Wimmer RA, Stahl M, Leopoldi A,
Garreta E, Hurtado Del Pozo C, Prosper F et al (2020) Inhibition of SARS-
CoV-2 infections in engineered human tissues using clinical-grade soluble
human ACE2. Cell 181: 905 – 913 e907
Mulangu S, Dodd LE, Davey Jr RT, Tshiani Mbaya O, Proschan M, Mukadi D,
Lusakibanza Manzo M, Nzolo D, Tshomba Oloma A, Ibanda A et al (2019)
A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J
Med 381: 2293 – 2303
Noma T (2005) Dynamics of nucleotide metabolism as a supporter of life
phenomena. J Med Invest 52: 127 – 136
Pizzorno A, Padey B, Dubois J, Julien T, Traversier A, Duliere V, Brun P, Lina B,
Rosa-Calatrava M, Terrier O (2020) In vitro evaluation of antiviral activity
of single and combined repurposable drugs against SARS-CoV-2. Antiviral
Res 181: 104878
Simonis A, Theobald SJ, F€atkenheuer G, Rybniker J, Malin JJ (2020) A
comparative analysis of remdesivir and other repurposed antivirals
against SARS-CoV-2. EMBO Mol Med https://doi.org/10.15252/emmm.
202013105
Stebbing J, Krishnan V, de Bono S, Ottaviani S, Casalini G, Richardson PJ,
Monteil V, Lauschke VM, Mirazimi A, Youhanna S et al (2020) Mechanism
of baricitinib supports artificial intelligence-predicted testing in COVID-19
patients. EMBO Mol Med 12: e12697
Tempestilli M, Caputi P, Avataneo V, Notari S, Forini O, Scorzolini L, Marchioni
L, Ascoli Bartoli T, Castilletti C, Lalle E et al (2020) Pharmacokinetics of
remdesivir and GS-441524 in two critically ill patients who recovered from
COVID-19. J Antimicrob Chemother 75: 2977 – 2980
Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D (2020)
Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein.
Cell 181: 281 – 292.e6
Wan Y, Shang J, Graham R, Baric RS, Li F (2020) Receptor recognition by
novel coronavirus from Wuhan: an analysis based on decade-long
structural studies of SARS. J Virol 94: e00127 – 20
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W,
Xiao G (2020a) Remdesivir and chloroquine effectively inhibit the
recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30:
269 – 271
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q et al
(2020b) Remdesivir in adults with severe COVID-19: a randomised, double-
blind, placebo-controlled, multicentre trial. Lancet 395: 1569 – 1578
Vorrink SU, Ullah S, Schmidt S, Nandania J, Velagapudi V, Beck O, Ingelman-
Sundberg M, Lauschke VM (2017) Endogenous and xenobiotic metabolic
stability of primary human hepatocytes in long-term 3D spheroid cultures
revealed by a combination of targeted and untargeted metabolomics.
FASEB J 31: 2696 – 2708
Vorrink SU, Zhou Y, Ingelman-Sundberg M, Lauschke VM (2018) Prediction of
drug-induced hepatotoxicity using long-term stable primary hepatic 3D
spheroid cultures in chemically defined conditions. Toxicol Sci 163:
655 – 665
Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS,
McLellan JS (2020) Cryo-EM structure of the 2019-nCoV spike in the
prefusion conformation. Science 367: 1260 – 1263
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B,
Huang CL et al (2020) A pneumonia outbreak associated with a new
coronavirus of probable bat origin. Nature 579: 270 – 273
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R
et al (2020) A novel Coronavirus from patients with pneumonia in China,
2019. N Engl J Med 382: 727 – 733
Zoufaly A, Poglitsch M, Aberle JH, Hoepler W, Seitz T, Traugott M, Grieb A,
Pawelka E, Laferl H, Wenisch C et al (2020) Human recombinant soluble
ACE2 in severe COVID-19. Lancet Respir Med 8: 1154 – 1158
License: This is an open access article under the
terms of the Creative Commons Attribution License,
which permits use, distribution and reproduction in
any medium, provided the original work is properly
cited.
8 of 8 EMBO Molecular Medicine e13426 | 2020 ª 2020 The Authors
EMBO Molecular Medicine Vanessa Monteil et al
